Articles tagged with Prostate Cancer
Researchers found that EZH2 expression was significantly higher in metastatic prostate cancer tissue compared to localized prostate cancer. A future test for high levels of EZH2 protein could serve as a red flag for physicians to identify men with the most aggressive form of the disease.
The initiative involves over 50 investigators in Seattle and Vancouver, B.C., aiming to develop improved therapies for men with recurrent or advanced disease. Prostate cancer affects one in six men, with an estimated 189,000 diagnoses this year and 30,200 deaths.
A new clinical trial is investigating the combination of high-dose calcitriol and docetaxel in treating advanced prostate cancer, with the goal of reducing PSA levels by 50% or more. The study builds on promising preliminary results from a previous Oregon Health & Science University trial.
Researchers have identified a genetic link between macrophage scavenger receptor-1 (MSR1) and increased risk of prostate cancer. MSR1 mutations were found in approximately 12.5% of African American men with prostate cancer, compared to 1.8% without the disease.
A research team led by Wake Forest and Johns Hopkins universities found that mutations in the MSR1 gene are associated with an increased risk of aggressive prostate cancer, particularly in African-American men. The study identified seven potentially important mutations of the MSR1 gene, including one that leads to rapid metastasis.
A recent analysis of eight PC-SPES lots revealed widespread contamination with indomethacin and diethylstilbestrol, two potent synthetic compounds that undermine the supplement's anticancer potency. The study suggests that the contaminated batches had significantly reduced anticancer activity.
A recent study of over 1,350 men found no correlation between a low-fat, high-fiber diet and reduced PSA levels over a four-year period. The study suggests that a healthy dietary pattern may still have an inhibitory effect on prostate cancer incidence despite the lack of impact on PSA levels.
A new study published in the Journal of Clinical Oncology found that a healthy diet does not significantly affect Prostate-Specific Antigen (PSA) levels over a relatively short period. The researchers believe that longer-term dietary effects on prostate cancer are still unknown.
Researchers at Cedars-Sinai Medical Center have found that a potent experimental drug called 2C4 slows tumor growth in both breast and prostate cancer tumors in mice, even when small amounts of HER-2/neu are expressed. The study's findings may lead to a new way to treat breast and prostate cancers.
A new study found that men with early-stage prostate cancer who follow a low-fat diet have half the risk of late-stage disease compared to those who consume more fat. Low-fat diets also reduced blood levels of testosterone, which fuels prostate growth and may contribute to cancer development.
Researchers at Michigan Medicine have discovered a new predictive marker, HIP1, associated with an increased risk of developing prostate and colon cancer. HIP1 levels were found to rise significantly in tumor cells, making it a potential target for therapy.
Researchers engineered a virus to target prostate-specific antigen, appearing as 'hot spots' in primary tumors and distant metastases. This method could deliver toxic treatments directly to prostate cancer cells, killing them while sparing surrounding healthy tissue.
The Prostate Interactive Educational System (PIES) is an interactive, computer-based program designed to provide comprehensive information tailored to the patient's preferences. The program will present disease and treatment information, a virtual support group, and allow patients to jot down notes in a virtual notebook.
Researchers will examine genes responsible for prostate cancer growth and identify potential diagnostic markers and therapeutic targets. The study aims to understand why prostate cancer spreads into bones, leading to a better understanding of this disease and potential treatments.
Researchers found that measuring Mcm5 levels in urine could detect bladder cancer with higher sensitivity than current tests. Additionally, a study linked effective DNA repair capacity to poorer survival rates in NSCLC patients treated with chemotherapy.
Researchers found that adding hormone-suppression therapy to radiotherapy for advanced prostate cancer significantly improved five-year disease-free survival rates. The study involved 415 patients, with those receiving combined therapy showing a substantial increase in overall survival rates.
A study finds that PSA testing led to a 29% and 44% overdiagnosis rate among white and black men, respectively. The increased incidence was partly due to unnecessary biopsies and side effects from treatment.
A new study conducted in New Zealand found no increased risk of prostate cancer among men who had undergone vasectomy. The study, which interviewed over 2,200 men, suggests that vasectomy does not pose a biological risk for prostate cancer.
A new test measures the ratio of cathepsin B to inhibitor stefin A in prostate tissue, revealing differences in tumors not visible under the microscope. The test can identify biologically aggressive and less aggressive forms of cancer, guiding treatment decisions for patients.
Researchers at Temple University discovered that the Rb2 gene's lack of expression could be an early indicator of prostate cancer. A study found lower expression levels of Rb2 in prostate tissue as it progresses from normal to cancerous, suggesting its potential use as a diagnostic marker.
This study estimates the direct and indirect costs of prostate cancer in California for 1998, finding that hospitalization costs account for almost three-fifths of total costs. Prostate cancer adds significant costs to patients with comorbid conditions, such as heart disease or respiratory illness.
A new study by Columbia University Irving Medical Center reveals significant differences in PSA (Prostate-Specific Antigen) and PSAD (Prostate-Specific Antigen Density) test measurements between Caucasian and Hispanic men. The study found that while PSAD can accurately predict cancer risk in Caucasians, it is less effective in Hispanic...
Researchers discovered a set of 511 genes that distinguish four groups of patients with benign prostatic hyperplasia (BPH), including those with symptoms and cancer. The findings suggest a potential link between BPH and prostate cancer, as well as a genetic 'field effect' in individuals with prostate cancer.
A recent study has challenged the long-held notion that African-Americans with prostate cancer have a poorer prognosis than their white counterparts. Researchers found that, when treated within clinical trial settings, African-American patients survived for an average of 15 months, comparable to 14-month survival rates for whites.
The study found patients who received the high-dose regimen had significantly longer overall and disease-free survival rates than those who received a lower dose. The company plans to initiate a Phase III trial of GVAX prostate cancer vaccine in the first half of 2003.
Researchers found that freezing cancer cells in test tubes increases their vulnerability to bleomycin, a potent anti-cancer drug. This combination therapy may lead to a powerful new form of cancer treatment targeting malignant cells while leaving healthy tissue unharmed.
Researchers at UIC are testing a new vaccine for advanced prostate cancer, targeting patients with a specific immune type. The vaccine uses a fragment of the protein PSA to stimulate the immune system and destroy tumor cells.
Hopkins researchers identified a nine-fold increase in expression of the AMACR gene in prostate cancers, making it a promising early marker and potential drug target. Overexpression patterns were also found in precancerous lesions, highlighting the gene's potential for non-invasive detection and prevention.
Researchers are developing a new method to improve the diagnosis of prostate cancer by using contrast-enhanced ultrasound. The study aims to identify areas in the prostate with more blood vessels, allowing for targeted biopsies and potentially reducing the number of unnecessary procedures.
Researchers found that a combination of targeted therapies can effectively inhibit tumor growth in prostate cancer. Using different drugs after resistance occurred inhibited tumor growth, suggesting multiple treatments may be needed to manage the disease. This approach is similar to how advanced breast cancer is treated today.
Prostate cancer tumors produce factors that inhibit dendritic cell growth and induce apoptosis, explaining immunological non-responsiveness in advanced patients. Stimulating dendritic cell growth is a promising area for future prostate cancer therapies.
The grant will allow Rush to increase awareness among African-American men aged 50+, who are disproportionately affected by prostate cancer. The organization plans to conduct free screenings and refer patients to local doctors or Rush after diagnosis.
Researchers have identified new markers for prostate and colon cancers, as well as a potential tumor suppressor gene. TIG1 was found to be expressed in normal prostate tissue but not malignant tumors, suggesting it may play a role in cancer progression.
Researchers at the University of Michigan have identified a gene, AMACR, which triggers production of a specific enzyme involved in fat metabolism. The protein is detected in over 95% of localized prostate cancer cells and shows high sensitivity and selectivity ratings for diagnostic purposes.
Men treated with ADT experienced increased complications, including impotence (80%), breast swelling, and hot flashes. Despite this, many reported feeling free of cancer after treatment.
A recent study published in the Mayo Clinic Proceedings found that daily NSAID use reduced prostate cancer risk by up to 60% in men aged 60 and older. The study, which followed 1,362 Caucasian men for an average of five and a half years, suggests that the beneficial effect may increase with age.
Late-stage prostate cancer unresponsive to hormone therapy due to hypermethylation of estrogen receptor genes. A new study suggests that demethylating agents could restore effectiveness of hormone therapy by reversing methylation.
Two new studies published in the Journal of the National Cancer Institute suggest that frequent tomato product consumption may reduce prostate cancer risk. Additionally, researchers found a possible role for the Ras gene in neuroblastoma regression and increased levels of GRP growth factor in head and neck cancers.
Evidence suggests PSA screening may not significantly reduce prostate cancer mortality rates. Large-scale randomized controlled trials are necessary to confirm these findings and provide clarity on the effectiveness of PSA screening at a population level.
A new PET tracer, 11C-acetate, has been found to detect prostate cancer earlier and more accurately than 18F-FDG PET. This breakthrough may enable the detection of cancers that are currently undetectable by conventional methods.
A diagnostic scan called capromab pendetide immunoscintigraphy can detect recurrent disease if it is localized to the area of prior prostate surgery or has spread to other parts of the body. The study found that this imaging tool is more sensitive than CT and bone scans in identifying the site and extent of disease recurrence.
A new study finds that prostate-specific antigen (PSA) is clinically unreliable for diagnosing prostate cancer, with low levels not meaningfully related to the disease. Prostate cancer is being over-diagnosed and over-treated due to a misconception about PSA's role in the disease.
A new prostate cancer vaccine developed at Duke University Medical Center has shown promising results, boosting the patient's immune system to fight cancer. The vaccine, made from the patient's own dendritic cells, causes no adverse side effects and activates T cell responses against tumor cells.
The Selenium and Vitamin E Cancer Prevention Trial, or SELECT, is the largest-ever clinical trial for prostate cancer prevention. The study aims to investigate whether taking selenium and vitamin E supplements can prevent prostate cancer in men of all races and ethnic backgrounds.
Scientists have identified a specific gene, RNASEL, in the HPC1 region linked to hereditary prostate cancer in some families. The study found mutations that inactivate this cellular self-destruct mechanism, explaining why some prostate cells become cancerous.
Researchers have identified matrix metalloproteinases as a key player in the spread of prostate cancer to the bone, offering a new target for treatment. Additionally, a genetic marker may be useful in predicting survival rates for patients with diffuse large B-cell lymphoma, while oral contraceptive use has been found to reduce ovarian...
Fewer than half the physicians surveyed thought early detection would reduce mortality rates. Routine screening was often offered due to perceived standard of care or fear of malpractice lawsuits.
A study by Stanford University urologist James D. Brooks confirms a direct connection between selenium and reduced risk of prostate cancer, particularly among older men with lower blood levels of the essential mineral.
Researchers at Johns Hopkins have developed a potential new screening test for prostate cancer by measuring the level of GSTP1 methylation in tissue samples. High levels of methylation were detected in 91.3% of early-stage cancers and 53.6% of precancerous lesions, suggesting its potential as an early diagnostic marker.
A new experimental drug called 2C4 has shown to significantly inhibit tumor growth in hormone-dependent and resistant prostate cancer tumors in mice. The monoclonal antibody targets the HER-2/neu protein, which controls cell growth and stimulates tumor growth.
Prostate cancer screening is a contentious issue due to its potential impact on quality of life and the need for well-informed decision-making. The article highlights the limitations of current research, including the lack of data on risk-benefit analysis and the importance of avoiding unnecessary anxiety and treatment.
The rate of prostate cancer diagnosis has increased significantly, with only 3-5% of newly diagnosed patients having advanced disease. However, the impact of this shift on mortality rates is uncertain, as PSA screening can lead to over-treatment and unnecessary aggressive treatment.
A new 'double suicide gene' therapy has shown promise in treating prostate cancer by carrying pairs of fused genes directly into cancer cells and inducing self-destruction. The technique achieved "greater levels of targeted cytotoxicity" than single suicide gene therapy, with minimal toxicities reported among patients.
Exisulind, a new selective apoptotic anti-neoplastic drug, delays disease progression in men with recurrent prostate cancer by slowing the rise of PSA levels. The study also found significant inhibition of tumor growth in mice, suggesting potential as a treatment option for advanced prostate cancer.
A new study from Massachusetts General Hospital found that medication pamidronate prevented bone loss in men with prostate cancer who received androgen-deprivation therapy. The study showed significant differences in bone mineral density between the treatment and control groups.
A large study of male physicians found that high calcium intake, particularly from dairy products, was associated with a 30-34% increased risk of prostate cancer. The authors suggest that this may be due to the suppression of vitamin D production, which is thought to protect against prostate cancer.
A computerized tool called Prostogram offers about 66% accuracy in predicting five-year prognosis following brachytherapy treatment for early-stage prostate cancer. The nomogram is based on individual factors such as PSA levels, Gleason score, and disease stage.
A study published by the American Chemical Society found that consuming three-fourths cup of tomato sauce daily for three weeks reduced DNA damage and PSA levels in 24 black volunteers with newly diagnosed prostate cancer. This suggests that eating extra tomato sauce may be beneficial to those at high risk for prostate cancer.
Researchers at U-M discovered nearly 200 genes with varying expression profiles in normal and malignant prostate tissue. The study identified new clinical biomarkers, hepsin and pim-1, which were correlated with patient prognosis and could lead to new diagnostic tests.
The study found that exisulind significantly suppressed the rise in PSA levels compared to placebo, especially in high-risk patients. Exisulind therapy also lengthened the median PSA doubling time, suggesting a delay in disease progression.